secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001193125-23-301829
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences dosed first patient in SURF201 for TYRA-200; TYRA-300 Part A clears dose cohorts; plans ACH IND H2 2024
--------------------------------------------------------------------------------

- First patient dosed in SURF201 Phase 1 study of TYRA-200 for FGFR2-altered cholangiocarcinoma and advanced solid tumors.
- SURF301 Part A dose escalation cleared multiple cohorts above anticipated dose for Phase 2 achondroplasia study.
- Expansion cohorts in SURF301 Part B at dose levels anticipated for oncology evaluation.
- Tyra plans to submit initial SURF301 Phase 1 results for a scientific congress in 2024.
- Company plans to submit IND for TYRA-300 in pediatric achondroplasia in H2 2024, starting with ages 5-12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312523301829/0001193125-23-301829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312523301829/d489661d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-301829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer